Research trials have found that the immunotherapy pembrolizumab more than doubled the 鈥榩rogression free survival鈥� time of patients with a specific subtype of bowel cancer. Honorary Associate Professor Dr Kai-Keen Shiu (UCL Cancer Institute) is Chief Investigator for the trials.
,听More: 皇家华人ews
Close
